Discover trends, market shifts, and competitive outlooks for the preclinical assets industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Preclinical Assets Market In 2029?
The market size for preclinical assets has witnessed robust growth over the recent years, expanding from $5.87 billion in 2024 to an expected $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. Factors such as the need for drug development, progress in biotechnology, regulatory mandates, increased funding for research, and partnership in research efforts have contributed to the growth experienced in the historical period.
The market size for preclinical assets is anticipated to exhibit a robust expansion in the coming years. By 2029, it’s predicted to surge to a value of $9.3 billion, with a compound annual growth rate (CAGR) of 9.8%. The expected growth during the forecast span can be credited to factors such as precision medication and personalized treatment methods, AI and machine learning implementation, expansion of biobanking, focus on rare illnesses, as well as government efforts and financial backing. During the forecast period, major emerging trends include the advent of advanced imaging techniques, development of 3D organoid models, integration of multi-omics methods, enhanced predictive models, as well as increased automation and high-throughput screening.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp
What External and Internal Drivers Are Contributing to the Growth of thePreclinical Assets Market?
The surge in drug discovery is anticipated to fuel the expansion of the preclinical asset market in the future. Drug discovery involves the identification of chemical substances that can serve as medicinal agents, leading to the birth of potential new medications. Preclinical assets are integral to this process, providing crucial data and evidence to assist in the selection of molecules for clinical development. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based group representing the pharmaceutical sector, highlighted significant growth in the European pharmaceutical industry with production rising from $352.48 billion in 2021 to $369.95 billion in 2022. Hence, the escalating rate of drug discovery is accelerating the growth of the preclinical assets market.
What Segment Types Define the Preclinical Assets Market Structure?
The preclinical assets market covered in this report is segmented –
1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users
Subsegments:
1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development
2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing
3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support
4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations
5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Preclinical Assets Market?
North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Long-Term Trends Are Transforming the Competitive Landscape of the Preclinical Assets Market?
The emergence of product innovations is a notable trend in the preclinical assets sector. Major players in this market are prioritizing the development of novel products and solutions to solidify their market standing and gain a competitive edge. For example, in April 2022, Charles River Laboratories International, an American pharmaceutical firm specialized in various preclinical and clinical laboratories, and Valo Health Inc., a tech firm from the US creating innovative drug discovery, introduced an AI-powered drug solution called Logica. This solution converts clients’ biological learnings into optimized preclinical assets. It takes advantage of Charles River’s advanced preclinical understanding and Valo’s Opal Computational Platform powered by AI to offer clients a revamped method of digging up new drugs. This integrated service seamlessly transitions clients’ targets to candidate nomination. Through collaborating with Valo, Charles River amalgamates its lab expertise with molecular design technology, thereby causing a profound transformation in the industry. It presents clients with highly competent leads and candidates, aligning client expenditure with value generation.
View the full report here:
https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report
What Is the Definition of the Preclinical Assets Market?
A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
